Nautilus Biotechnology (NASDAQ: NAUT) net income
Nautilus Biotechnology reported a net loss of $59.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $70.8m. Earnings per share were −$0.47.
Nautilus Biotechnology's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$59.0m | — | — | −$0.47 |
| 2024 | −$70.8m | — | — | −$0.56 |
| 2023 | −$63.7m | — | — | −$0.51 |
| 2022 | −$57.9m | — | — | −$0.46 |
| 2021 | −$50.3m | — | — | −$0.60 |
| 2020 | −$15.6m | — | — | −$0.54 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Nautilus Biotechnology net income compared with its sector
By net income for its latest fiscal year, Nautilus Biotechnology ranks 272nd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 270th | Protara Therapeutics | −$57.4m | — |
| 271st | Lucid Diagnostics | −$58.0m | −1,232.7% |
| 272nd | Nautilus Biotechnology | −$59.0m | — |
| 273rd | Adaptive Biotechnologies | −$59.5m | −21.5% |
| 274th | Onkure Therapeutics | −$59.5m | −1,729.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Nautilus Biotechnology
- How much did Nautilus Biotechnology earn in fiscal 2025?
- Nautilus Biotechnology reported a net loss of $59.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $70.8m.
- What are the earnings per share of Nautilus Biotechnology?
- They were −$0.47 in fiscal 2025, compared with −$0.56 in fiscal 2024.
- Where does Nautilus Biotechnology rank in its sector by net income?
- It ranks 272nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Nautilus Biotechnology come from?
- From the annual report (Form 10-K) that Nautilus Biotechnology files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Nautilus Biotechnology files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Nautilus Biotechnology: the Nautilus Biotechnology page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.